European Journal of Molecular & Clinical Medicine (EJMCM)
ISSN: 2515-8260 Volume 09, Issue 03, 2022

Development and characterization Theophylline and budesonide, a hydrophilic and lipophilic medication, are co-encapsulated

Deepa.N*[1], Prithivirajan. E[2], Elaveyini. E[3], Gnanisha. M[4], Thamizharasi. S[5], Tamil Selvan.S[6], Suryanarayanan. P[7], Kishan Kumar. S.B[8], Tamilanban. D[9], Sandhiya .V[10], Swarnamugi. G[11] Ramya. P[12], Sherlin Kirubha. T[13]

Saveetha College of Pharmacy, Saveetha Institute Of Medical and Technical Sciences, Thandalam, Chennai, Tamil Nadu, India.

Corresponding Author: Dr.Deepa.N Email: deepanatarajan@yahoo.com

Abstract

Drug-encapsulated biodegradable polymeric nanoparticles are suitable for therapeutic molecule delivery to the lungs. The current study sought to encapsulate a hydrophilic drug (theophylline) and a lipophilic drug (budesonide) in poly(lactic acid) (PLA) nanoparticles for pulmonary drug delivery. PLA nanoparticles were created using a double emulsification solvent diffusion method and were evaluated for particle size, zeta potential, drug loading, in vitro drug release, interactions with an airway epithelial cell line (16HBE14o-), and in vitro deposition properties upon nebulization. The spherically-shaped mono- and co-encapsulated PLA nanoparticles had particle sizes ranging from 190 to 400 nm and a zeta potential ranging from 10 to 16mV. Sustained drug release from nanoparticles into a mixture of simulated lung fluid and methanol (1:1) was observed over 24 hours when measured using Franz diffusion cells and when assessed for permeability using 16HBE14o-cells. After 24 hours of exposure to drug-encapsulated nanoparticles at nebulized concentrations, there was no significant reduction in cell viability ($p > 0.05$). Nebulization of co-encapsulated nanoparticles yielded a fine particle fraction of 75% for theophylline and 48% for budesonide, respectively. Based on these findings, it is possible to conclude that budesonide and theophylline drug-loaded PLA nanoparticles are appropriate drug delivery systems for combination therapy of asthma and COPD.

Key Words: Drug Encapsulated , Biodegradable , Mono and co- Encapsulated , Nano particles

INTRODUCTION:

Nanoparticles are created from several synthetic and natural polymers for various medication delivery objectives [1]. Many studies have shown that nanoparticles can be used to encapsulate mostly lipophilic drugs with biodegradable polymers to create a prolonged profile of releases of drugs. Examples include synthetic polyesters, such as lactic acid (PLA), polyesters (PLGA), polyesters, like poly(caprolactone) and natural biodegradable polymers (including chitosan, albumin, gelatine, alginate) [2, 3]. The PLA and PLGA polyesters are metabolized by citric acid & pyruvate cycles in the body and produce non-toxic byproducts such as carbon dioxide, water & nitrogen to organic metabolites, like lactic or glycolic acid [4, 5, 6]. These polymers are thought to not affect normal cell activity because of their gradual breakdown and production of natural metabolites [7, 8]. Nanoparticles to transport drugs through the lungs has been

extensively studied. Drugs for breathing disorders, including asthma & chronic pulmonary obstruction illness, are ideal for direct consumption (COPD) [9, 10]. Like Theophylline and Budesonide-packed PLGA particles, many medicines were designed as possible Mikro and Nanoparticular formulations or investigated for pulmonary drug deliverance. They include budesonide, fluticasone propionate, voriconazole, levofloxacin, siRNA, antibiotic, anti-cancer medicines and insulin [11, 12]. Theophylline, mast cell resistance, & leukotriene antagonists are among the most common drugs currently available on oral formulations to treat lung disorders. It's thought that combining budesonide and Theophylline improves the therapeutic impact.

Aim and Objective:

This study aimed to design a formula to extend the dosing interval and increase patient adherence, providing lengthy releases of both medicinal products.

Material and Methods:

Purace Biomaterials (Purace), The Netherlands was provided with poly (lactic acid) (PLA) (Purasorb® PDL02; molecular weight - 17,000 kda). The poly(vinyl alcohol) (PVA) (molecular weight – 15,000) and poly(4,5-dimethyl2-thiazolyl)-2,5-diphenyl2-tetrazole poly(99%) anhydrate powder) and 3-(4,5-dimethyl-2-thiazolylates) have been supplied by SIGMA Aldrich (MTT).LKT Laboratories supplied the budesonide. Laboratory quality and HPLC were all other products and solvents. Life Technologies bought trypan blue stain (0.4% w/v). Medicell membranes provided the membrane of cellulose (dialysis vising tube). Unless otherwise specified, Fisher Scientific Ltd purchased all reagents and supplies used in cells culture. The generously supplied 16HBE 14o cells previously by Professor Dieter Gruenert.For monoencapsulated nanoparticles, Theophylline–PLA 1:4 weight/weight ratio and co-incapsulated Theophylline–budesonide–PLA nanoparticles were produced 1:40, and nanoparticles 10:1:40. A modified DESD process was used to manufacture mono- and co-encapsulated PLA nanoparticles. In the emulsion préparation, nanoparticles were created in the same way as co-encapsulated nanoparticles but not using budesonide or Theophylline. PLA (organic) and PVA (aqueous) solutions are the only way to manufacture blank nano parts. In the PerkinElmer Spectrum 65 IR-Spectrometer, a global ATR sample analyzer examined the surface characteristics of nanoparticles (UK). All samples were compared to medication and polymer standards for freeze-dried nano parts. A scanning range of 400–4000 cm1 and a resolution of 4 cm were chosen. At60-minute intervals up to 6 hours and at 24 hours, samples were obtained from the basolateral chamber (200 L). For the determination of drug concentration or FD4 in the sample, HPLC & fluorescence spectroscopy were used. The FD4 concentration was established with a 485/20 nm wavelength and 528/20 Nm emission wavelength reader Biotech Gen5. The apparent coefficient of permeability (Papp) of each chemical was computed with Equation (1):

$$Papp = (dq /dt) \times A.Co$$

When (dq/dt) is the pace at which the sample is transported, A is the surface area of the Transwell. C0 is the drug or FD4 concentration provided in the apical room at the beginning. All measurements have been made at least three times, and all findings indicate a mean and standard deviation. The comparison of the sample was carried out statistically using Mann-Whitney, One-Way ANOVA (physical-chemical) &Twoway ANOVA test. With a p-value of less than 0.05, the observations were judged significantly different (95 per cent probability).

Results and Discussion:

Various literature techniques have been recorded to encapsulate medicinal products in nanoparticles, such as monomer polymerization, emulsion-solvent evaporation, nanoprecipitation, salting, etc. Since hydrophilic medications are more intimate with the exterior aqueous phase, hydrophobic medicines can be encapsulated simpler than hydrophilic pharmaceuticals, leading to a lower cargo efficiency. The present technique to DESD led to nanoparticles being successfully produced. In the encapsulation of the hydrophilic pharmaceutical (Theophylline), The insertion of a second organic solvent combined with water, acetone/acetonitrile/ethyl acetate, assists in separating the organic from the aqueous phases of this medicine.

Table 1: the effect of blank nanoparticles of theophylline and Budesonide and mono and co-encapsulated theophylline and budesonide on the apparent permeability of FD4 across 16HBE14- cells (n=3) blank nanoparticles or 9 remaining studies, mean ±SD

Time period	0 – 6 h	6 – 24 h	0 – 24 h
	Papp ($x10^{-6}$ cm/s)	Papp ($x 10^{-6}$ cm/s	Papp ($x10^{-6}$ cm/s)
Control Blank PLA NPs	0.04±0.01 0.07±0.01	0.12±0.01 0.14±0.01	0.11±0.01 0.13±0.00
Control Theophylline solution Budesonide solution	0.11±0.02 0.14±0.03 0.20±0.01	0.21±0.01 0.15±0.01 0.16±0.02	0.14±0.02 0.12±0.02 0.18±0.01
Control Mono-encapsulated theophylline Mono – encapsulated budesonide	0.08±0.01 0.07±0.01 0.06±0.01	0.17±0.01 0.13±0.02 0.12±0.01	0.15±0.02 0.17±0.01 0.11±0.01
Co-encapsulated theophylline and budesonide	0.12±0.01	0.11±0.02	0.24±0.01

. For these research applications, the FD4 paper was identical to the FD4 paper in controlcells ($p> 0.05$) between cells treated with theophylline or budesonide solutions or drug encapsulated nanoparticles.

The technique has been tweaked and improved to improve nanoparticles' load efficiency in various ways. Differences in drug or PLA concentrations; duration of emulsion homogenization; procedures for organic layer évaporation (rotative evaporation at negative or simple continuous gaiter pressure); Molecular weight variations (9K–205K) or surfactant PVA (0.5 to 5% W/v)

concentrations; alteration in organic solar concentrations in the secondary soil (Table 1). Surfactants like Tween 80, Lutrol F127 and sodium dodecyl sulphate have been investigated for PVA substitutes. In addition, the TER of the cell layers of 16HBE14o showing that the cells had a functioning barrier was 210. To assess the efficacy of the solutions containing Theophylline, budesonide, mono- or co encapsulated drugs, and the integrity of the barrier, paracellular diffusion markers 16HBE14o-cells were utilized to detect FD4 permeability. The FD4 card ranged between 0.12 0.01 106 (n + 3) and 0.18 0.01 106 (n = 9) cm/s over 24 hours in control cells. There was no impact on this ($p>0.05$) when blank nanoparticles were included. The FD4 paper was identical to the FD4 paper in control cells ($p> 0.05$) between cells treated with theophylline or budesonide solutions or drug encapsulated nanoparticles for these research applications.

These findings support the findings of the cytotoxicity investigation that show that formulations of nanoparticles are not cell-dangerous. Compared to the francophyllin and budesonide cell-release tests, the drug permeability of cells to solution cells was compared to that of the Franz diffusive cell tests. The findings showed that nanoparticles were carried through the cells slower than the medication solution, and nanoparticles could prolong their release.

CONCLUSION:

The MMAD droplet was estimated at 2,30 m for the theophylline-containing formulation and 3,54 m for the budesonide-containing formulation, respectively. The findings show that the formula for inhalation in the co-encapsulated nanoparticles with a droplet of 5 m and a reasonably high FPF in Theophylline and budesonide are appropriate. Despite changes in medication administration, the findings of deposit studies suggest that all these drugs can be used in the correct lung zone, depending on the drug supply type used

References:

1. Bajracharya, R., Song, J. G., Back, S. Y., & Han, H. K. (2019). Recent Advancements in Non-Invasive Formulations for Protein Drug Delivery.In *Computational and Structural Biotechnology Journal*. https://doi.org/10.1016/j.csbj.2019.09.004
2. Hastedt, J. E., Bäckman, P., Clark, A. R., Doub, W., Hickey, A., Hochhaus, G., Kuehl, P. J., Lehr, C.-M., Mauser, P., McConville, J., Niven, R., Sakagimi, M., &Weers, J. G. (2016). Scope and relevance of a pulmonary biopharmaceutical classification system AAPS/FDA/USP Workshop March 16-17th, 2015 in Baltimore, MD.*AAPS Open*. https://doi.org/10.1186/s41120-015-0002-x
3. Theory and Practice of Contemporary Pharmaceutics. (2021). In *Theory and Practice of Contemporary Pharmaceutics*. https://doi.org/10.1201/9780203644478
4. Zhang, Q., Zhang, P., Jian, S., Li, J., Li, F., Sun, X., Li, H., Zeng, Y., Zeng, Y., Liang, S., Chen, P., & Liu, Z. (2020). Drug-Bearing Peptide-Based Nanospheres for the Inhibition of Metastasis and Growth of Cancer.*Molecular Pharmaceutics*. https://doi.org/10.1021/acs.molpharmaceut.0c00118
5. Li, Q., Zhan, S., Liu, Q., Su, H., Dai, X., Wang, H., Beng, H., & Tan, W. (2018). Preparation of a Sustained-Release Nebulized Aerosol of R-terbutaline Hydrochloride Liposome and Evaluation of Its Anti-asthmatic Effects via Pulmonary Delivery in Guinea Pigs.*AAPS PharmSciTech*. https://doi.org/10.1208/s12249-017-0816-z

6. Hastedt, J. E., Bäckman, P., Clark, A. R., Doub, W., Hickey, A., Hochhaus, G., Kuehl, P. J., Lehr, C.-M., Mauser, P., McConville, J., Niven, R., Sakagami, M., &Weers, J. G. (2016). Erratum to: Scope and relevance of a pulmonary biopharmaceutical classification system AAPS/FDA/USP Workshop March 16-17th, 2015 in Baltimore, MD. *AAPS Open*. https://doi.org/10.1186/s41120-016-0005-2
7. Farooq, S. M., Sunaina, S., Rao, M. D. S., Venkatesh, P., Hepcykalarani, D., &Preama, R. (2020). Floating Drug Delivery Systems: An updated Review.*Asian Journal of Pharmaceutical Research*. https://doi.org/10.5958/2231-5691.2020.00009.x
8. Faria-Urbina, M., Ung, K. T., Lawler, L., Zisman, L. S., & Waxman, A. B. (2021). Inspiratory flow patterns with dry powder inhalers of low and medium flow resistance in patients with pulmonary arterial hypertension.*Pulmonary Circulation*. https://doi.org/10.1177/20458940211012591
9. Pindiprolu, S. K. S. S., Kumar, C. S. P., Kumar Golla, V. S., Likitha, P., K, S. C., EsubBasha, S. K., &Ramachandra, R. K. (2020). Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent.*Medical Hypotheses*. https://doi.org/10.1016/j.mehy.2020.109858
10. Miles, M. C., Donohue, J. F., &Ohar, J. A. (2013). Nebulized arformoterol: What is its place in the management of COPD? In *Therapeutic Advances in Respiratory Disease*. https://doi.org/10.1177/1753465812465784
11. Labiris, N. R., &Dolovich, M. B. (2003). Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. In *British Journal of Clinical Pharmacology*. https://doi.org/10.1046/j.1365-2125.2003.01893.x
12. Patel, N., & Panda, S. (2012). Liposome drug delivery system: a critic review. Journal of Pharmaceutical Science and Bio-scientic Reseearch.